Autoimmune Connect –
All Blogs
The NIH Report: “Enhancing NIH Research on Autoimmune Disease”
May 2022 Report This May 2022 549-page NIH report represents a significant breakthrough in autoimmune research focus. Its recommendations have major downstream implications for CDC statistics, basic research, R&D, medical education & clinical guidelines. Funded and launched in 2019, before the pandemic but even more relevant since COVID-19 spotlighted post-viral
Siloed Specialties & Treatments for Autoimmune Diseases
Autoimmune Diseases are Siloed by Specialty Click the arrows next to the slide to view the sources. Looks a mess, doesn’t it? It is! Autoimmune diseases are scattered across many different medical specialties, creating a siloed landscape in which patients must coordinate and navigate for themselves. This illustration maps high-prevalence
The Chronic Disease Epidemic: Visible & Invisible
The Visible Chronic Disease Epidemic Click the arrows next to the slide to view the sources. The chronic disease population has grown substantially in recent years since modern medicine has extended the human lifespan. Depending on sources, 40-60% of Americans (128-140M people) have one or more chronic health conditions. Moreover,
A Patient Journey Solution (Part 3): Digitally Enabled V1C
A solution to convoluted autoimmune patient journeys?
Digitally enabled, virtual first care (V1C) offers a potential solution to convoluted autoimmune patient journeys. V1C especially offers significant advantages for autoimmune and inflammatory disease (AIID) patients in accessing specialized care. Virtual specialist practices get patients to a rheumatologist or gastroenterologist much faster (days rather than months) and with less
The Autoimmune Patient Journey (Part 2)
A Deeper Dive into the Loops
Many Convoluted Stages Along AIID Patient Journeys The convoluted journey of patients with autoimmune and inflammatory diseases (AIIDs) has many stages. Each stage presents challenges that may cause patients to drop out before they get the care they need. Unlike cancer, diabetes, and heart disease, there are no population screening
The NIH Report: “Enhancing NIH Research on Autoimmune Disease”
May 2022 Report This May 2022 549-page NIH report represents a significant breakthrough in autoimmune research focus. Its recommendations have major downstream implications for CDC statistics, basic research, R&D, medical education & clinical guidelines. Funded and launched in 2019, before the pandemic but even more relevant since COVID-19 spotlighted post-viral
Siloed Specialties & Treatments for Autoimmune Diseases
Autoimmune Diseases are Siloed by Specialty Click the arrows next to the slide to view the sources. Looks a mess, doesn’t it? It is! Autoimmune diseases are scattered across many different medical specialties, creating a siloed landscape in which patients must coordinate and navigate for themselves. This illustration maps high-prevalence
The Chronic Disease Epidemic: Visible & Invisible
The Visible Chronic Disease Epidemic Click the arrows next to the slide to view the sources. The chronic disease population has grown substantially in recent years since modern medicine has extended the human lifespan. Depending on sources, 40-60% of Americans (128-140M people) have one or more chronic health conditions. Moreover,
A Patient Journey Solution (Part 3): Digitally Enabled V1C
A solution to convoluted autoimmune patient journeys?
Digitally enabled, virtual first care (V1C) offers a potential solution to convoluted autoimmune patient journeys. V1C especially offers significant advantages for autoimmune and inflammatory disease (AIID) patients in accessing specialized care. Virtual specialist practices get patients to a rheumatologist or gastroenterologist much faster (days rather than months) and with less
The Autoimmune Patient Journey (Part 2)
A Deeper Dive into the Loops
Many Convoluted Stages Along AIID Patient Journeys The convoluted journey of patients with autoimmune and inflammatory diseases (AIIDs) has many stages. Each stage presents challenges that may cause patients to drop out before they get the care they need. Unlike cancer, diabetes, and heart disease, there are no population screening